|
|
Article: Efficacy and Safety Clinical Data for Rigel's R112 Phase II Study Published in Journal of Allergy and Clinical Immunology; Rigel's R112 Compound, an Inhibitor of Syk Kinase, Shows Promise for the Treatment of Allergic Rhinitis.
- Article from:
- PR Newswire
- Article date:
- April 6, 2005
CopyrightCOPYRIGHT 2005 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
SOUTH SAN FRANCISCO, Calif., April 6 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. today announced that the Journal of Allergy and Clinical Immunology has published the Phase II clinical data for R112, the company's lead candidate for the treatment of allergic rhinitis. The article titled, "An Intranasal Syk-kinase inhibitor (R112) improves the symptoms of seasonal allergic rhinitis in a park environment," is included in the April 2005 issue of the Journal. The article reviews the clinical Phase II data results for R112, concluding that patients in a park-like setting demonstrated a significant improvement in their allergic rhinitis symptoms when treated with ...